Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer

Basit Öğe Kaydı
dc.contributor.authorUgrakli, Muzaffer
dc.contributor.authorAraz, Murat
dc.contributor.authorDemirkiran, Aykut
dc.contributor.authorcelik, Ahmet Faruk
dc.contributor.authorKarakurt Eryilmaz, Melek
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:27:02Z
dc.date.available2024-02-23T14:27:02Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIntroduction Trastuzumab emtansine (TDM-1) is an antibody-drug conjugate effective in human epidermal growth factor receptor-2 - expressing advanced breast cancer. Pulmonary complications of TDM-1 are rarely reported. TDM-1-associated interstitial lung disease is referred to as pneumonitis. Case report A 47-year-old female patient who underwent modified radical mastectomy and axillary lymph node dissection operations due to a palpable mass in the right breast and axillary region. The patient who had received multiple chemotherapy was last receiving TDM-1 treatment. Fatigue, dyspnea, and tachypnea were detected for the first time on 20 days after the 6(th) treatment. Menagement and outcome In our case, we first considered metastasis, pneumonia and fungal infection based on radiological findings, but the lack of response to the treatments and the results of the investigations suggested drug-induced pneumonia and steroid treatment was started. Our case had a complete radiological recovery and complete response to sterod therapy. In such cases, it is important to first exclude infections and metastasis. In cases of drug-induced pneumonia, the first treatment option is systemic corticosteroids and generally responded well. Discussion Unlike other cases of interstitial pneumonia, lung imaging of our case was resembling a metastasis, pneumonia and fungal infection. With increasing use of TDM-1, we will have more experience in both efficacy and complications of TDM-1. Although TDM-1 is a well-tolerated drug, clinicians should be aware of rare pulmonary complications and prepared to respond appropriately.en_US
dc.identifier.doi10.1177/10781552211066073
dc.identifier.endpage745en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue3en_US
dc.identifier.pmid34935553en_US
dc.identifier.scopus2-s2.0-85122142657en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage740en_US
dc.identifier.urihttps://doi.org/10.1177/10781552211066073
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14428
dc.identifier.volume28en_US
dc.identifier.wosWOS:000736348500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdo-Trastuzumab Emtansineen_US
dc.subjectTdm-1en_US
dc.subjectPneumonitisen_US
dc.subjectInterstitial Pneumonitisen_US
dc.subjectBreast Canceren_US
dc.titlePneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu